@article{b4a4d5b1572d4cb7b364d821787379f9,
title = "Combination Doxorubicin and Pembrolizumab in Patients with Advanced Anthracycline-Naive Sarcoma - Reply",
author = "Wagner, \{Michael J.\} and Cranmer, \{Lee D.\} and Pollack, \{Seth M.\}",
note = "Funding Information: Conflict of Interest Disclosures: Dr Muralidhar reported receiving a grant from the Conquer Cancer Foundation outside the submitted work. No other disclosures were reported. Funding Information: Conflict of Interest Disclosures: Dr Wagner reported receiving personal fees from Adaptimmune Therapeutics and Deciphera Pharmaceuticals and research support to institution from Incyte, GlaxoSmithKline, and Athenex outside the submitted work. Dr Cranmer reported receiving grants to institution from Merck during the submitted work; grants to institution from Eli Lilly and Company, Aadi Bioscience, BluePrint Medicines, Iterion Therapeutics, Gradalis, Advenchen Laboratories, CBA Pharma, Exelixis, and Philogen and personal fees from BluePrint Medicines and Regeneron Pharmaceuticals outside the submitted work. Dr Pollack reported receiving grants from Merck during the submitted work; and grants from EMD Serono, Incyte, Presage Biosciences, Juno Therapeutics, and OncoSec Medical and personal fees from Daiichi Sankyo and GlaxoSmithKline outside the submitted work.",
year = "2021",
month = mar,
doi = "10.1001/jamaoncol.2020.7873",
language = "English (US)",
volume = "7",
pages = "465--466",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "3",
}